Size Matters: NIH Patents Brain-Targeting Drug Tech Exclusively
Published Date: 4/22/2025
Notice
Summary
The National Cancer Institute is planning to give Sangam Lifesciences an exclusive patent license for a cool new drug delivery technology that targets the brain and lymph system based on size. This means Sangam gets special rights to develop and sell this invention, which could speed up better treatments. If you’re in biotech or healthcare, keep an eye out—this deal could shake things up soon!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Exclusive NIH Patent License Award
The National Cancer Institute is considering granting an exclusive patent license to Sangam Lifesciences, Inc., a company in Denver, Colorado, for a macromolecular drug delivery technology that targets brain and lymphatic distribution. The license would allow Sangam to practice the inventions embodied in the patent applications listed in the notice's Supplementary Information.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in